黃芪是常用的補(bǔ)氣類中藥，是典型的多效中藥。臨床上以黃芪為君藥的復(fù)方不勝枚舉，功效十分廣泛，僅目前《中國(guó)藥典》中收載的含黃芪的復(fù)方就有200多種。然而，現(xiàn)行的質(zhì)量評(píng)價(jià)方法難以準(zhǔn)確判斷黃芪藥材的優(yōu)劣，更無(wú)法有效關(guān)聯(lián)黃芪在不同復(fù)方配伍環(huán)境中的定向功效。鑒于黃芪藥材的多效性，急需新的技術(shù)與思路，構(gòu)建符合中醫(yī)藥辯證論治觀的質(zhì)量評(píng)價(jià)體系。綜述目前黃芪藥材質(zhì)量評(píng)價(jià)的研究進(jìn)展，并從質(zhì)量標(biāo)志物的尋找策略出發(fā)提出關(guān)于黃芪質(zhì)量評(píng)價(jià)的新的見(jiàn)解和策略。

Astragali Radix is a common traditional Chinese medicine for tonifying qi, which is a typical multi-effect Chinese medicine. Clinically, there are many formulas take Astragali Radix as one principal drug, and exert extensive pharmacological efficacies. At present, there are more than 200 kinds of formulas containing Astragali Radix contained in the Chinese Pharmacopoeia Commission. However, the current quality evaluation of Astragali Radix is difficult to evaluate its effectiveness relevant to its oriented pharmacodynamic action associated with the compatible environment in formulas under the particular pathologic conditions. Thus, a novel approach is urgently needed to construct a quality evaluation system that conforms to the dialectical view of Chinese medicine. This paper reviews the current research progress of the quality evaluation of Astragali Radix and proposes new insights and strategies.

國(guó)家自然科學(xué)基金資助項(xiàng)目（31770362；81703697）